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ABSTRACT
Objective: This study was done to determine the relationship between donor chimerism
and the presence of her -abl gene in chronic myeloid leukaemia (CML) patients post-
transplantation. Methods: The study population consisted of all CML patients who had
undergone non-myeloablative peripheral blood stem cell transplant in Hospital Universiti
Kebangsaan Malaysia (HUKM) during the study period. All patients had their bone
marrow aspiration done at diagnosis and day 30, 60, 100, 130, 160 and 190 post-
transplantation. The samples were analysed for her -abl transcript as well as chimerism
status. Results: A total of nine cases underwent non-myeloablative peripheral blood stem
cell transplant. All patients were transplanted during the chronic phase. One patient was
found to show mixed chimerism at day 30 post-transplant coinciding with her -abl transcript
disappearance. Six patients showed that full donor chimerism con'elated with her -abl
transcript disappearance. In one patient, chronic myeloid leukaemia transformed into
acute myeloid leukaemia. Another patient had a graft failure. Conclusion: This
observational cohort study showed that full chimerism is required for disappearance of
her -abl transcript but one case showed disappearance of her -abl transcript at day 30 while
full chimerism was not achieved.
IN T R O D U C T IO N
Chronic myeloid leukaemia (CML) was first recognised as early as in 1845 when several
cases presented with splenomegaly, anaemia and massive granulocytosisJ1.2] It was the
discovery of Philadelphia (Ph) chromosome in 1960 that led to a better understanding of the
pathogenesis of the disease. It took another thirteen years before the Ph chromosome was
shown to be generated by a specific translocation involving chromosomes 9 and 2 2 . In the
1980s, the bcr -abl fusion oncogene was described, and found to be transcribed and translated
into a functional protein. Finally, in 1990, the first definitive evidence of the ability of bcr -
abl protein to transform primary myeloid cells and induce a CML-like disease in mice was
published. [ I)
Conclusi ve evidence of CML relies on cytogenetic and molecular studies to detect the
t(9; 22) (q34; q II) translocation. The Ph chromosome is an acquired cytogenetic abnom1ality
that characterises all leukaemic cells in CML. However, it is not pathognomonic for CML as
it is present in 25-50% of adult patients with acute lymphoblastic leukaemia and in 2% with
acute myelogenous leukaemiaYl It was the first chromosomal abnormality associated with
a specific malignancy. [3 )
In CML transplantation, three strategies have been developed that include the use of
reduced intensity preparative regimens, the induction of tolerance between host and donor
immune systems by creating a mixed chimaeric state after transplant and optimising graft
versus leukaemic effect by increasing the speed and completeness of donor immune recovery.
These approaches are collectively grouped under the term 'non-myeloablative stem cell
transplant' or called as 'minitransplant'.
P a tient Sample
Bone marrow samples was collected with patients' consent from the haematology wards of
HUKM. Ethical committee approval was obtained from HUKM. Selection criterion was
CML patients who had undergone minitransplant. An exclusion criterion was CML patients
who only received medications. Nine patients had their bone marrow aspiration done at
diagnosis, day 30 post-transplant, day 60 post-transplant, day 100 post-transplant, day 130
post-transplant and day 160 post-transplant. The samples were analysed for bcr -abl
transcripts as well as chimerism status.
Mononuclea r Cell Extra ction from Bone Ma r row Aspira tion
Mononuclear cell isolation was performed by gradient density centrifugation on Ficoll-
Hypaque (Amersham Pharmacia Biotech Ab, Uppsala, Sweden). Cells were washed to
remove excess Ficoll-Hypaque. The cells were spun at 1000 rpm for 10 minutes to obtain cell
pellet. The supematant was decanted.
Chimer ism Assessment by Shor t Tandem Repea ts
DNA extraction
200 .ul binding buffer and 40 .ul proteinase K were added to 200 .ul of the bone marrow
specimen. The mixture was mixed immediately and incubated for 10 minutes at n ° e . 100.u1
of isopropanol was added and the mixture was applied to a h i g h pure filter tube and centrifuged
for I minute at 8000 rpm. Then 500 .ul of wash buffer was added and centrifuged for I minute
at 8000 rpm. A new tube and 200 .ul of elution buffer were added before centrifuging the
mixture for I minute at 8000 rpm. The micro centrifuge tube then contained eluted nucleic
acid.
DNA quantification
The purity and quantity of DNA were determined by spectrophotometer. The ratio of
wavelength reading at 260:280 nm was between 1.8-2.0. The DNA concentration was
estimated by measuring its absorbance at 260 nm.
DNA amplification
The master mix was prepared by using 21 p i ofthe reaction mix, 11 p i of the primer set and 1.0
p i of the Ampli Taq Gold (Applied Biosystems, Foster City,Canada). The mixture was
vortexed for 5 seconds and 30 p I was pipetted into each PCR tube. 20 p i of DNA and
positive control were added into the PCR tubes respectively. In the negative control tube,
20 p i of the TE buffer was added. All tubes were placed into the GeneAmp PCR system 9700
(Applied Biosystems, Foster City, Canada) instrument.
Acrylamide gel electrophoresis
Acrylamide gel electrophoresis was done by using the ABI Prism 377 instrument. Once the
gel temperature reached 51°C, 1.5 pi of DNA sample was injected using the flat tip into each
of the sample loading areas.
Bcr-abl Sta tus Assessment by RT-PCR
RNA was extracted according to the manufacturer's instructions as described before.
Following that, the RNA was converted to cDNA. 8 p i of cDNA sample and I p i of Taq
Polymerase were mixed with the PCR mix which contained 2.4 p i of PCR buffer, 0.9 p i of
MgCl2, 0.48 pi of dTPs, 0.112,ul ofCA3, 0.106,ul ofC5e, 0.100 ,ulofB2B, 0.088,ul ofBCR-C and
11.812 pi of distilled water. The mixture was amplified using thermal cycle 480 and the
product was run onto agarose gel for electrophoresis. The band was visualised using
ultraviolet light.
Clinica l F ea tures
A total of nine cases of CML underwent non-myeloablative peripheral blood stem cell
transplant in Hospital Universiti Kebangsaan Malaysia during the study period (Table 1).
All patients presented and were transplanted during the chronic phase. Eight patients were
transplanted within one year of diagnosis of CML. However, one patient (CML 9) was
transplanted 4 years after he had been diagnosed to have CML. All except one were males.
The median age was 32 years (range 15-49 years). Four were Malays while five were
Chinese.
All patients had high total white cell count at presentation, with the lowest being
16.0xl09/1 and the highest 231.0x109/1. CML Patient 6 had the biggest spleen size at
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T ab le 1 . Patients characteristics
Patient Age Gender Ethnic Total white Spleen Liver Ber -abi at
group blood cell diagnosis
CMLI 23 Male Malay 60.0x 109/L 3cm 4cm Positive
CML2 28 Male Chinese 231.0 x 109Jl 15cm 6cm Positive
CML3 37 Male Chinese 36.6 x 109Jl 2cm nil Positive
CML4 49 Male Malay 45.6 x 109Jl 7cm lcm Positive
CML5 17 Male Malay 63.2 x 109/1 12cm 3cm Positive
CML6 35 Female Malay 150.0x 109Jl 16cm 6cm Positive
CML7 40 Male Chinese 23.4 x 109/1 5cm 2cm Positive
CML8 15 Male Chinese 16.0 x 109/1 3cm lcm Positive
CML9 49 Male Chinese 47,5 x 109/1 4cm nil Positive
presentation and she also had a hepatomegaly of 6 cm. All patients exhibited ber -abi gene
transcripts positivity pre-transplant.
Chimer ism Sta tus and bcr-abl Ana lysis
All patients had ber -abl analysis done pre-transplant and all were found to be positive.
Both ber -abi and chimerism study were performed on day 30, 60, 100, 130, 160 and day 190
post -transplantation.
CML Patient I attained mixed chimerism at day 60 post-transplant, however ber -abi
still showed positivity. He only attained complete chimerism at day-130 post-transplant
and simultaneous disappearance of the ber -obl transcripts. The same findings were observed
for CML Patient 2. In the case of CML Patient 3, he attained complete chimerism and
disappearance of the ber -obl transcripts at day 100 post transplant. In CML Patient 4, after
day-IOO post transplant, analysis still showed no chimerism; he received donor lymphocyte
infusion. Subsequently, only at day 160 post transplant did he achieve complete chimerism
together with the disappearance of the ber -abl transcripts. He also did not experience any
graft versus host disease (GVHD) which may delay ber -abi transcripts clearance. Whereas
CML Patient 5 showed graft failure signs at day 60 post transplant and subsequently
received donor lymphocyte infusion. Further, at day 100 post transplant, he did not achieve
any chimerism status. Only at day 130 post transplant, did he show complete chimerism as
well as disappearance of the ber -abl transcripts. CML Patient 6 achieved transient mixed
chimerism at day 30 post transplant, but reverted to no chimerism status for the subsequent
analysis. She received donor lymphocyte infusion two times, at day 120 and day 180 post-
transplant; however, her leukaemic cells failed to clear. Patient CML 7 achieved complete
chimerism status and disappearance of the ber -abl transcripts faster than the other patients
described before and this status persisted throughout the study period. Patient CML 8 was
the unique patient; at day 30 post-transplant, he showed mixed chimerism as well as
disappearance of the ber -abl transcripts. Subsequently, he achieved complete chimerism
which persisted. Patient CML 9 showed mixed chimerism and persistently positive ber -abl
CC - Complete chimerism
NC - No chimerism
MC - Mixed chimerism
transcripts. At day 100 post-transplant, he showed signs oftransforrnation to acute leukaemia
with his peripheral blood showing presence of blast cells. He immediately received donor
lymphocyte infusion but it failed to kill the leukaemic cells. Subsequent analysis showed
no chimerism and presence of the bcr - abl transcripts.
D IS C U S S IO N
In the CML patients studied, 55.5% were Chinese whereas 44.4% were Malays. There was
a marked gender difference in this group of patients with 88.8% being male and 11.1% being
female. The median age at presentation was 32 (range 15-49 year old) compared to SC Ng
et a l. 141 who found the age at presentation to be 34.9 years while Hamidah et a l. [51 reported
the mean age at presentation to be 34.8 years. It appears that Malaysian CML population is
younger compared to the West. The reason is not clear but could be due to the lower
average age of the Malaysian population compared to the population in the West.[4]
In this study, the chronic leukaemia of CML Patient 9 transformed into acute leukaemia
after day 90 post-transplantation. Though initially, he attained mixed chimerism, promising
for engraftment, the mixed chimerism failed to sustain. At the time he showed haematological
transformation into acute leukaemia, he had received donor lymphocyte infusion (DLI).
Donor lymphocyte can restore complete remission but is only effective in about 70% of
cases with a failure rate of 30%.16]
Some studies indicate that mixed chimeras may be at higher risk of relapse [7.8,9Jwhile
other studies do not corroborate this finding.[9,IO,'I]No conclusion can be drawn from our
small series. To date, many investigators believed that CML patients need complete donor
chimerism to eliminate the ber -abl transcripts. Our study appears to support this belief as
complete chimerism was observed to correlate with clearance of ber -abl transcripts. Seven
out of nine patients attained complete chimerism simultaneously with the disappearance of
the ber -abl transcripts. In one of the studies carried out[121, the authors found immune
reconstitution after transplantation showing a complete chimerism state had significantly
higher subsets ofCD2, CD3, CD4, CDS and CD6 cells than that of the mixed chimeric state.
In our series, one patient (CML 8) managed to eliminate his ber -abl transcripts while he
was only at mixed chimerism state. The reasons for such a finding could be as follows:
1 . NK cells after transplant are higher in a mixed chimeric state [121.NK cells are capable of
cytolytic activity against residual tumour cells. So this could be one of the possibilities
why his mixed chimerism state appeared to eliminate his ber -abl transcripts.
2. The persistence of recipient cells in a mixed chimeric state results in the continued
presence of allo-antigens (e.g. minor histo-compatibility antigens) unfamiliar to the donor
origin of T cell precursors [131. Evidence suggests that such minor histo-compatibility
plays an important role in the OVHD and graft versus leukaemia (OVL) effect.[13] An
increasing number of minor histo-compatibility antigens have been identified and it has
been shown that the expression of some minor his to-compatibility antigens is restricted
to haematopoietic cells and leukaemia cells.[14]
3. It could be that the residual disease in this patient is more sensitive and fragile to
immune control by the graft compared to the other patients.
4. The last reason could be that he underwent the transplantation at a stage where his
residual disease is very low and this facilitated clearance of ber -abl transcripts by the
graft.
C O N C L U S IO N
This observational cohort study showed that full chimerism is essential for disappearance
of ber -abl transcripts. However, one patient did not require full chimerism state to clear the
disease. Further studies need to be carried out to elucidate the mechanisms of tumour
clearance without full chimerism.
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